7 July 2003 in The Journal of Pathology
11 September 2008 in Endocrinology
In addition to the core circadian oscillator, located within the suprachiasmatic nucleus, numerous peripheral tissues possess self-sustaining circadian timers. In vivo these are entrained and temporally synchronized by signals conveyed from the core oscillator. In the present study, we examine circadian timing in the lung, determine the cellular localization of core clock proteins in both mouse and human lung tissue, and establish the effects of glucocorticoids (widely used in the treatment of asthma) on the pulmonary clock. Using organotypic lung slices prepared from transgenic mPER2::Luc mice, luciferase levels, which report PER2 expression, were measured over a number of days. We demonstrate a robust circadian rhythm in the mouse lung that is responsive to glucocorticoids. Immunohistochemical techniques were used to localize specific expression of core clock proteins, and the glucocorticoid receptor, to the epithelial cells lining the bronchioles in both mouse and human lung. In the mouse, these were established to be Clara cells. Murine Clara cells retained circadian rhythmicity when grown as a pure population in culture. Furthermore, selective ablation of Clara cells resulted in the loss of circadian rhythm in lung slices, demonstrating the importance of this cell type in maintaining overall pulmonary circadian rhythmicity. In summary, we demonstrate that Clara cells are critical for maintaining coherent circadian oscillations in lung tissue. Their coexpression of the glucocorticoid receptor and core clock components establishes them as a likely interface between humoral suprachiasmatic nucleus output and circadian lung physiology. There is a glucocorticoid-sensitive circadian clock within the lung. The bronchial epithelial Clara cells play a critical role in pulmonary circadian timing.
11 October 2012 in European Respiratory Journal
The p38 mitogen-activated protein kinase (MAPK) pathway is upregulated in chronic obstructive pulmonary disease (COPD). To date, dual labelling to identify cell-type-specific presence of phosphorylated (phospho-)p38 MAPK has not been carried out.Phospho-p38 MAPK was quantified in a variety of cell types in the lung tissue of 20 COPD patients, 12 smokers and 12 nonsmokers using immunohistochemistry. Paired blood and sputum neutrophils (from seven subjects with COPD), and CD8 and epithelial cells (from three subjects with COPD) were cultured with a p38 MAPK inhibitor. Supernatant tumour necrosis factor-α and CXCL8 levels were analysed by ELISA. Sputum and blood neutrophil cytospins were analysed for phospho-p38 MAPK.Phospho-p38 MAPK was increased in bronchial epithelial cells, macrophages and CD20+ and CD8+ lymphocytes in COPD lungs. Sputum and lung tissue neutrophils were devoid of phospho-p38 in all patient groups. The p38 MAPK inhibitor SB100 attenuated pro-inflammatory mediator release in COPD lung CD8 cells and airway epithelia, but there was no effect on COPD sputum neutrophils.Our data indicate cell-specific anti-inflammatory effects of p38 MAPK inhibition in the lung.
21 June 2013 in European Respiratory Journal
Peroxisome proliferator-activated receptor (PPAR)-γ is expressed in alveolar macrophages. The anti-inflammatory potential of the PPAR-γ ligands rosiglitazone and pioglitazone were investigated usingin vitroalveolar macrophage models andin vivoanimal models relevant to chronic obstructive pulmonary disease (COPD).PPAR-γ protein and gene expression in COPD alveolar macrophages was compared with control smokers and never-smokers. COPD macrophages were used to investigate the effects of PPAR-γ ligands and corticosteroids on lipopolysaccharide-induced cytokine production, alternative macrophage activation (M2) gene expression and efferocytosis. The effects of PPAR-γ ligands in a subchronic tobacco smoke model in mice were investigated.PPAR-γ protein expression was similar in COPD patients compared to controls, although increased gene expression levels were observed in COPD patients and control smokers compared to never-smokers. PPAR-γ ligands reduced tumour necrosis factor-α and CC chemokine ligand-5, but not CXC chemokine ligand-8, in COPD alveolar macrophages; these effects were generally less than those of the corticosteroid dexamethasone. Rosiglitazone increased M2 gene expression and enhanced efferocytosis of apoptotic neutrophils. Rosiglitazone and pioglitazone attenuated airway neutrophilia in a corticosteroid-resistant mouse model of pulmonary inflammation.We show biological actions of PPAR-γ agonists on corticosteroid-resistant disease, tobacco smoke-induced pulmonary inflammation, skewing of macrophage phenotype and clearance of apoptotic neutrophils.
21 February 2012 in British Journal of Pharmacology
BACKGROUND AND PURPOSE IFN‐γ levels are increased in chronic obstructive airway disease (COPD) patients compared with healthy subjects and are further elevated during viral exacerbations. IFN‐γ can ‘prime’ macrophages to enhance the response to toll‐like receptor (TLR) ligands, such as LPS. The aim of this study was to examine the effect IFN‐γ on corticosteroid sensitivity in alveolar macrophages (AM).EXPERIMENTAL APPROACH AM from non‐smokers, smokers and COPD patients were stimulated with IFN‐γ and/or LPS with or without dexamethasone. IL‐6, TNF‐α and IFN‐γ‐induced protein 10 kDa (IP‐10) levels were measured by elisa, and Western blots were used to investigate the IFN‐γ‐stimulated Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signalling pathway. Real‐time PCR and flow cytometry were used to investigate TLR levels following IFN‐γ treatment.KEY RESULTS In all three subject groups, IFN‐γ alone had no effect on IL‐6 and TNF‐α production but enhanced the effects of LPS on these cytokines. In contrast, IFN‐γ alone increased the production of IP‐10. IFN‐γ increased TLR2 and TLR4 expression in AM. Cytokine induction and STAT1 activation by IFN‐γ were insensitive to dexamethasone for all groups. The inhibition of JAK and STAT1 repressed all these IFN‐γ effects.CONCLUSIONS AND IMPLICATIONS Our results demonstrate that IFN‐γ–induced STAT‐1 signalling is corticosteroid resistant in AMs, and that targeting IFN‐γ signalling by JAK inhibitors is a potentially novel anti‐inflammatory strategy in COPD.